With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing ...

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

Amanda Bynes revealed that she plans to use the injectable drug Ozempic to help achieve her weight loss goals, noting she ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

With the weight-loss blockbuster drug Wegovy, now in India, renowned endocrinologist and diabetologist Dr. Ambrish Mithal ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...

Wegovy, to be in pharmacies by the end of June, has been launched in a pen-injection format with strengths ranging from 0.25 ...

Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...